The first vaccine derived from cowpox

The British rural doctor could not forget the words of the peasant girl. Could that really be true? A couple of decades later, on 14 May 1796, he performed the ...

Anna Törner: To kill your darlings

Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of excit...

Miljonstöd till 14 life science-projekt för bättre hälsa

Nya tekniker för fixering av handfrakturer, AI-prediktion av blodtrycksfall och tidig detektion av bukspottkörtelcancer finns bland de 14 projekt för bättre häl...

Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Scien...

Lucy Robertshaw: There is a bio revolution happening right now

Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.

Samuel Lagercrantz: Immunotherapy against cancer is still in its early stages

For more than 100 years, researchers have tried to target the body’s own immune system to fight cancer cells. They have occasionally been laughed at and ridicul...

Column: "Are we already living in the new normal?"

2020 felt like the year that we were building the house around us whilst moving into it at the same time.

Pharma Outsourcing igång på Stockholm Waterfront

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Giulia Gaudenzi: Innovation for good

"I challenge the innovator landscape to take a mental leap. Relying on innovation-solely to end inequality is not enough, therefore consciously and purposively ...

Rätt läkemedel till rätt patient – ett paradigmskifte på väg

Ett nytt sätt att se på läkemedel mot cancer har gjort sitt intåg – läkemedel som förskrivs vid en viss genmutation istället för vid en viss cancersjukdom. Det ...

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of De...

New diagnostic test soon ready for the market

Swedish top scientists to EMBO

Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and one is from the University of Uppsala....

Swedish Healthtech Company 1928 Pushing Forward

The full service analytics platform is expanding the business.

From spin-off to phase II

”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.

Hallengren tar plats i global grupp mot antibiotikaresistens

Socialministern en av 26 ledamöter i gruppen.

New partnering platform

EBD Group's Partnering One is the new partnering platform for Biotech Forum 2009.

Lif vill ha "nationell ingång" för hälsodata även i Sverige

Sverige behöver förbättra tillgängligheten till hälsodata för forskning och innovation, anser branschorganisationen Lif, som tycker att vi borde snegla mot våra...

Pilots want to live too

Brexit looking back and looking forward

More than 3 years have passed after the vote and there is still uncertainty around the outcome although the UK December 12 election set a clearer course towards...

It´s time to establish relations

Communication with the patient is the key to future healthcare, writes Hanna Brodda, editor in chief of Life Science Sweden.

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...